PL2476436T3 - Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych - Google Patents

Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych

Info

Publication number
PL2476436T3
PL2476436T3 PL11187013T PL11187013T PL2476436T3 PL 2476436 T3 PL2476436 T3 PL 2476436T3 PL 11187013 T PL11187013 T PL 11187013T PL 11187013 T PL11187013 T PL 11187013T PL 2476436 T3 PL2476436 T3 PL 2476436T3
Authority
PL
Poland
Prior art keywords
immunogenic peptides
immunological disorders
immunological
disorders
immunogenic
Prior art date
Application number
PL11187013T
Other languages
English (en)
Inventor
Jean-Marie Saint-Remy
Original Assignee
Life Sciences Research Partners Vzw
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0615966A external-priority patent/GB0615966D0/en
Priority claimed from GB0710081A external-priority patent/GB0710081D0/en
Priority claimed from GB0711403A external-priority patent/GB0711403D0/en
Application filed by Life Sciences Research Partners Vzw, Katholieke Universiteit Leuven filed Critical Life Sciences Research Partners Vzw
Publication of PL2476436T3 publication Critical patent/PL2476436T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01008—Iodide peroxidase (1.11.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
PL11187013T 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych PL2476436T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0615966A GB0615966D0 (en) 2006-08-11 2006-08-11 Novel therapy for immune disorders
GB0710081A GB0710081D0 (en) 2007-05-25 2007-05-25 Novel cellular therapy for immune disorders
GB0711403A GB0711403D0 (en) 2007-06-13 2007-06-13 Therapy for immune disorders
EP11187013.5A EP2476436B1 (en) 2006-08-11 2007-08-13 Immunogenic peptides and their use in immune disorders
EP07801643.3A EP2059256B1 (en) 2006-08-11 2007-08-13 Immunogenic peptides and their use in immune disorders

Publications (1)

Publication Number Publication Date
PL2476436T3 true PL2476436T3 (pl) 2018-05-30

Family

ID=38626589

Family Applications (3)

Application Number Title Priority Date Filing Date
PL07801643T PL2059256T3 (pl) 2006-08-11 2007-08-13 Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
PL11187013T PL2476436T3 (pl) 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
PL11187012T PL2476435T3 (pl) 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07801643T PL2059256T3 (pl) 2006-08-11 2007-08-13 Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11187012T PL2476435T3 (pl) 2006-08-11 2007-08-13 Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych

Country Status (10)

Country Link
US (4) US9249202B2 (pl)
EP (4) EP2476436B1 (pl)
JP (2) JP5750600B2 (pl)
AU (1) AU2007283731B2 (pl)
CA (2) CA2926004A1 (pl)
DK (3) DK2476435T3 (pl)
ES (4) ES2709176T3 (pl)
PL (3) PL2059256T3 (pl)
PT (3) PT2476436T (pl)
WO (1) WO2008017517A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5750600B2 (ja) 2006-08-11 2015-07-22 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルクＬｉｆｅ Ｓｃｉｅｎｃｅｓ Ｒｅｓｅａｒｃｈ Ｐａｒｔｎｅｒｓ Ｖｚｗ 免疫原性ペプチドおよび免疫障害におけるその使用
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
DK2083856T3 (da) 2007-08-15 2011-01-24 Circassia Ltd Peptider til desensibilisering mod allergener
AU2014259586B2 (en) * 2008-02-14 2017-01-05 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
CA2715517C (en) * 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in preventing or treating allograft rejection
AU2009214041A1 (en) * 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
EP2249864B1 (en) * 2008-02-14 2016-05-04 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
EP2719396B1 (en) * 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
CA2715488C (en) * 2008-02-14 2019-09-24 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
EP2252329B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
JP5942296B2 (ja) * 2010-03-29 2016-06-29 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ 少なくとも１つのｃｘｘｃモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2012069568A2 (en) * 2010-11-25 2012-05-31 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
WO2013083140A1 (en) 2011-12-07 2013-06-13 N.V. Nutricia Beta-lactoglobulin peptides for treating cow's milk protein allergy
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
IN2014DN08964A (pl) * 2012-04-30 2015-05-22 Imcyse Sa
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
BR112015023024B1 (pt) * 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
PT3065771T (pt) 2013-11-04 2019-06-24 Uti Lp Metodos e composicoes para imunoterapia prolongada
WO2015100360A1 (en) * 2013-12-23 2015-07-02 Alk-Abelló A/S Peptide combinations and uses thereof in treating dust mite allergy
EP2982746A1 (en) * 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
AU2016275312B2 (en) 2015-05-06 2021-12-23 Uti Limited Partnership Nanoparticle compositions for sustained therapy
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
WO2017040976A1 (en) 2015-09-02 2017-03-09 Erkki Ruoslahti Compounds and compositions for targeting brain injuries and methods of use thereof
WO2019113342A1 (en) 2017-12-07 2019-06-13 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for treating nervous system injuries
ES2874077T3 (es) * 2015-09-25 2021-11-04 Imcyse Sa Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos
SG11201808710UA (en) 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
JP7122002B2 (ja) * 2017-03-01 2022-08-19 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
IL268874B2 (en) 2017-03-09 2023-09-01 Imcyse Sa Peptides and methods for treating diabetes
EP3388447A1 (en) 2017-04-14 2018-10-17 Imnate Sarl Methods to produce peptides, polypeptides or cells for modulating immunity
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
US20220233568A1 (en) 2017-10-19 2022-07-28 Curevac Ag Novel artificial nucleic acid molecules
AU2018374569B2 (en) 2017-11-29 2024-10-17 Uti Limited Partnership Methods of treating autoimmune disease
CN110317246B (zh) * 2018-03-28 2022-08-02 深圳市安群生物工程有限公司 人mog抗原表位肽、抗原、抗体、应用及化学发光试剂盒
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
JP2022532409A (ja) * 2019-05-16 2022-07-14 アンシス・エスア 改変されたシステインを含む酸化還元酵素モチーフを有する免疫原性ペプチド
EP3756648A1 (en) 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations
WO2021105371A1 (en) 2019-11-27 2021-06-03 Imcyse Sa Methods for stratifying diabetes patients
WO2021184080A1 (en) * 2020-03-20 2021-09-23 Monash University Compositions and methods for treating lupus
CA3182369A1 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
AU2021210629A1 (en) 2020-05-06 2022-12-08 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
CA3181635A1 (en) 2020-05-06 2021-11-11 Imcyse Sa Immunogenic peptides with new oxidoreductase motifs
US20240189404A1 (en) * 2020-05-06 2024-06-13 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations
CN117750971A (zh) 2021-05-26 2024-03-22 易姆赛斯股份公司 治疗或预防自身免疫病的方法
JP2024520952A (ja) 2021-06-01 2024-05-27 アンシス・エスア 免疫原性ペプチドを使用した改善された処置方法
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1985004103A1 (en) 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
FI931393L (fi) 1990-09-27 1993-03-26 Syntello Vaccine Dev Kb Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
EP0623168B1 (en) 1991-10-16 2009-09-30 Merck Patent GmbH T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US20030152581A1 (en) * 1998-07-30 2003-08-14 Jean-Marie Saint-Remy Compound and method for the prevention and/or the treatment of allergy
AR020102A1 (es) * 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
CN1230444C (zh) 1998-11-16 2005-12-07 德克萨斯州立大学董事会 含有hiv细胞毒t淋巴细胞表位的hiv多肽或肽或其多聚核苷酸表达构建体的用途
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
JP4776852B2 (ja) 2000-01-28 2011-09-21 アメリカ合衆国 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ
GB0006437D0 (en) 2000-03-17 2000-05-10 Leuven Res & Dev Vzw Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
US20030104570A1 (en) 2000-06-26 2003-06-05 Cabezon Silva Teresa Elisa Virginia Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
ES2404689T3 (es) * 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
WO2002097070A1 (en) 2001-05-30 2002-12-05 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
DE60231417D1 (de) 2001-10-03 2009-04-16 Unilever Nv Kohlenhydratbindungsdomäne enthaltende fusionsproteine zur verabreichung von therapeutischen und anderen stoffen und zusammensetzungen in denen die fusionsproteine enthalten sind
US20100183652A1 (en) 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
AU2003215395A1 (en) 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
CA2478930A1 (en) * 2002-04-01 2003-10-16 Euro-Celtique, S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
DK2261249T3 (en) * 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
JP2004147649A (ja) * 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
JP2003289887A (ja) * 2003-02-13 2003-10-14 Univ Harvard 免疫調節ペプチド
EP1609107A4 (en) 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
JP5097400B2 (ja) 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
GB0324265D0 (en) * 2003-10-16 2003-11-19 Medical Res Council Peptide
US20070184023A1 (en) 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
EP2332971B1 (en) 2004-06-17 2016-02-17 MannKind Corporation Epitope analogs
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US8486411B2 (en) 2005-08-30 2013-07-16 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
FR2898275B1 (fr) 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
JP5750600B2 (ja) 2006-08-11 2015-07-22 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルクＬｉｆｅ Ｓｃｉｅｎｃｅｓ Ｒｅｓｅａｒｃｈ Ｐａｒｔｎｅｒｓ Ｖｚｗ 免疫原性ペプチドおよび免疫障害におけるその使用
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2205252B1 (en) 2007-09-27 2017-04-05 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
CA2715517C (en) 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in preventing or treating allograft rejection
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2249864B1 (en) 2008-02-14 2016-05-04 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
CA2715488C (en) 2008-02-14 2019-09-24 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
EP2252329B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
WO2009101201A2 (de) 2008-02-15 2009-08-20 Chemetall Gmbh Mischungen aus metallhydriden und ionischen flüssigkeiten und verwendungen solcher mischungen
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9764012B2 (en) 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
JP5942296B2 (ja) 2010-03-29 2016-06-29 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ 少なくとも１つのｃｘｘｃモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用
WO2012069568A2 (en) 2010-11-25 2012-05-31 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
AU2013220079B2 (en) 2012-02-15 2017-10-05 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201319160D0 (en) 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
ES2874077T3 (es) 2015-09-25 2021-11-04 Imcyse Sa Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos
SG11201808710UA (en) 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
IL268874B2 (en) 2017-03-09 2023-09-01 Imcyse Sa Peptides and methods for treating diabetes
US20210401976A1 (en) 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
JP2022532409A (ja) 2019-05-16 2022-07-14 アンシス・エスア 改変されたシステインを含む酸化還元酵素モチーフを有する免疫原性ペプチド
CA3182369A1 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
AU2021210629A1 (en) 2020-05-06 2022-12-08 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
CA3181635A1 (en) 2020-05-06 2021-11-11 Imcyse Sa Immunogenic peptides with new oxidoreductase motifs
US20240189404A1 (en) 2020-05-06 2024-06-13 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs

Also Published As

Publication number Publication date
EP2476435A2 (en) 2012-07-18
US20240034759A1 (en) 2024-02-01
EP2476435B1 (en) 2017-12-20
EP2059256B1 (en) 2016-08-03
US9249202B2 (en) 2016-02-02
PL2059256T3 (pl) 2017-02-28
EP2059256A1 (en) 2009-05-20
US20160194367A1 (en) 2016-07-07
AU2007283731A1 (en) 2008-02-14
US20100303866A1 (en) 2010-12-02
CA2926004A1 (en) 2008-02-14
ES2657480T3 (es) 2018-03-05
AU2007283731B2 (en) 2013-10-24
CA2660605A1 (en) 2008-02-14
ES2657504T3 (es) 2018-03-05
WO2008017517A1 (en) 2008-02-14
CA2660605C (en) 2016-05-17
US11718650B2 (en) 2023-08-08
JP5750600B2 (ja) 2015-07-22
JP2010500308A (ja) 2010-01-07
JP2015142578A (ja) 2015-08-06
EP2476436A3 (en) 2014-01-01
DK2476435T3 (en) 2018-03-05
DK2476436T3 (en) 2018-02-05
ES2601432T3 (es) 2017-02-15
US20200317742A1 (en) 2020-10-08
EP2476436B1 (en) 2017-11-29
PT2476436T (pt) 2018-02-23
EP2476436A9 (en) 2014-07-23
EP2476436A2 (en) 2012-07-18
US10662232B2 (en) 2020-05-26
ES2709176T3 (es) 2019-04-15
PT2059256T (pt) 2016-11-08
PL2476435T3 (pl) 2018-05-30
EP2476437A3 (en) 2014-01-01
EP2476437B1 (en) 2018-11-28
PT2476435T (pt) 2018-03-05
EP2476437A2 (en) 2012-07-18
EP2476435A3 (en) 2014-01-01
DK2059256T3 (en) 2016-12-05

Similar Documents

Publication Publication Date Title
PL2476435T3 (pl) Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
PL2502938T3 (pl) Przeciwciała i immunokoniugaty oraz ich zastosowanie
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
SI3620171T1 (sl) Protitelesa proti GM-CSF in uporabe zanje
DK1991564T3 (da) Virosomlignende vesikler omfattende gp41-afledte antigener
BRPI0816789A2 (pt) Goji e inflamação
IL205780A0 (en) Fviii peptides and their use in tolerising haemophiliacs
FR2868881B1 (fr) Titre en anglais
DE602005020202D1 (de) Getrennter Steckverbinder und Verbindereinrichtung
PL2040668T3 (pl) Kopolimery do stosowania w stylizacji włosów
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
EP1746104A4 (en) NEW SOLUBLE CD14-ANTIGEN
DE602006003063D1 (de) Tripeptid- und tetrapeptidsulfone
SI1858481T1 (sl) Oftalmološki sestavki in njihova uporaba
GB0615635D0 (en) Immunogenic proteins and uses thereof
EP1773386A4 (en) VACCINE COMPOSITIONS AND METHODS
DK1840121T3 (da) Glycinderivat og anvendelse heraf
ZA200801874B (en) Antigenic peptides and their use
EP2046815A4 (en) INFLAMMATORY AND ANTIALLERGIC CYCLIC PEPTIDES
IL181228A0 (en) Vlp-antigen conjugates and their uses as vaccines
DE602005015944D1 (de) Entspannungsstuhl
ITFI20060204A1 (it) Lampada e dispositivo antidispersione luminosa in direzioni indesiderate
ITFI20060316A1 (it) Telecomandi in busvie e tranvie
ITGE20040086A1 (it) Valvole in sincronia
ZA200701667B (en) VLP-antigen conjugates and their use as vaccines